Knowledge Hub

Treatment of vaccine-preventable pneumococcal disease carries a heavy financial toll for health systems and families

In a study in The Gambia – a setting where healthcare is free of charge to patients – pneumococcal disease nonetheless placed a heavy financial burden on families seeking treatment before arrival at the hospital, with families paying for transportation costs, drugs, diagnostic tests and even burial in the case of death. 50-80% of the cost of treating an episode of pneumococcal disease was born by the health system, which still left families to cover a cost up to 10 times their average daily household budget. In addition the estimated treatment cost for inpatient pneumonia of US$109 is nearly 4 times the annual per capita expenditure for health in The Gambia.

Full Citation:
Usuf, E., Mackenzie, G., Sambou, S., et al. 2016. The economic burden of childhood pneumococcal diseases in The Gambia. Effectiveness and Resource Allocation. 14(4).

Title of Article: The economic burden of childhood pneumococcal diseases in The Gambia

Author(s): Usuf, E., Mackenzie, G., Sambou, S., et al

Publication Year: 2016

Publication Name: Effectiveness and Resource Allocation

Publication Volume: 14(4)

Publication Source URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4758012/

DOI (Digital Object Identifier): 10.1186/s12962-016-0053-4

Topics: Economics & Return on Investment

Disease Vaccines: Pneumococcal disease/PCV/PPSV | Pneumonia

Countries: Gambia

WHO Regions: Africa